Bio-Techne stock
TECHNASDAQBio-Techne Corporation, HealthcareISIN US09073M1045
65Score 65 out of 100, Neutral
Price and trend
85 / 100
Price history
+23% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 15% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 61).
The price is at its 52-week high. Largest decline in 20 years: 68% (September 2021 to May 2026).
Chart figures for advanced users
- SMA 50$72.52
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$63.30
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)61
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$43.30
- The lowest closing price of the last twelve months.
- Resistance$72.83
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Bio-Techne Corporation belongs to the Biotechnology industry (United States) and, with a market value of $11.44B, is number 32 of 296 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $1.22B (down 0.4% year on year) and earnings of $181.86M (up 147.8%).
- For fiscal 2027, analysts expect on average revenue of $1.27B (up 4.5%) and adjusted earnings per share of $2.05 (up 6.2%).
Show more
- MEQIRI Score 65 out of 100 (Neutral): rank 218 of 714 in Healthcare, median 53.
- The P/E is 66.9 (Biotechnology median 21.3, own median of recent years 58.4).
- Our model puts fair value at $29.58, with the price 146% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 179% of earnings over the last 12 months.Fundamentals 87
- Reliable dividendNo dividend cut for 18 years.
- Consistently profitableProfit in all 10 fiscal years from 2017 to 2026.Fundamentals 87
Weaknesses
- Above fair valuePrice 146% above the fair value of $29.58.Valuation 13
Its standout strengths are fundamentals and technical analysis, while growth and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- solid fundamentals
- price near its 52-week high
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $21.13 and expensive above $49.29 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $35.97 (cash-flow model) and $23.18 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 9.3%. At 10.3% the fair value would be $26.74, at 8.3% it would be $33.67.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 0.9% on the twelve months before. Revenue has grown solidly since 2007, at about 9% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 66%, operating 21%, net 15%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 2 Feb 2027in 82 days
- Last reported
- 9 Nov 2026EPS reported $0.44 (expected $0.44)in line with expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $2.05+0.8%
- Revenue
- $1.27B+0.1%
- Earnings per share
- $2.36−0.8%
- Revenue
- $1.4B+0.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −10.2%Fourth quarter organic growth expected to be approximately flat; the forecast stays flat as long as no clear market improvement is visible.
“Taking these market and customer-specific dynamics into account, we expect organic growth in the fourth quarter to be approximately flat.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 May 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Bio-Techne
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 65
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Madrigal PharmaceuticalsMDGL $12.67B34
- Pharmaron Beijing300759.SZ $12.15B58
- Financière de TubizeTUB.BR $11.9B50
- Halozyme TherapeuticsHALO $11.59B80
- BioMarin PharmaceuticalBMRN $11.3B50
- VaxcytePCVX $10.8B46
- Akeso9926.HK $10.58B32
- Sichuan Kelun Pharmaceutical002422.SZ $10.43B70
ETFs that hold Bio-Techne
Held by 31 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Genomics & Biotechnology UCITS ETFGN0M | 3.39% | 0.50% | €127.06M |
| iShares Healthcare Innovation UCITS ETF2B78 | 1.11% | 0.40% | €1.49B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.22% | 0.43% | €2.48B |
Show 5 more
| Xtrackers S&P 500 Equal Weight UCITS ETF 2C EUR HedgedXDEE | 0.20% | 0.30% | €14.88B |
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 0.17% | 0.15% | €592.11M |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 0.16% | 0.15% | €3.27B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.14% | 0.35% | €434.1M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.11% | 0.35% | €8.19B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 30 Jun 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 3 Oct 2025)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.